Harvard Business Review

JANUARY 5, 2012

For the past few decades, emerging technologies such as biotechnology, microelectronics, information technology and communications technologies have become central to the socioeconomic development of nations. Yes, they know more about mobile operating systems and mobile payments than they do about farming! The farms are now IT labs.

Information Technology 17

Information Technology Technology Information Trends 17

Harvard Business Review

MAY 2, 2011

Without operating in the former, they won't be able to attain economies of scale; sans the latter, they're unlikely to continue developing state-of-the-art technologies. Another CEO of a fast-growing biotechnology venture, a Chinese-American entrepreneur, added that he wanted his company to be perceived as American rather than as Chinese.

Globalization 15

Globalization Marketing Venture Capitalist Biotechnology 15

Harvard Business Review

OCTOBER 26, 2011

Their behavior displays promising parallels to the early days of the biotechnology industry. When biotechnology startups like Genentech began to acquire other startups to retain their edge, pharmaceutical incumbents were forced to enter the acquisition melee to remain competitive.

Energy 13

Energy Finance IPO Biotechnology 13

Harvard Business Review

MARCH 2, 2012

As global companies focus their strategies on developed and emerging markets, they require substantial cadres of leaders capable of operating effectively anywhere in the world. economy, expands America's global trade, and attracts foreign companies to base operations in the U.S.

Competitive Advantage 15

Competitive Advantage Globalization Development Intellectual Capital 15

Harvard Business Review

FEBRUARY 17, 2011

The reason for the interest in in part because the industry has suffered from poor returns on investment over the last decade; indeed, some sectors, including biotechnology, report negative aggregate returns. China and India, in particular, offer attractive liquidity and investment opportunities VCs haven't seen for a while.

Marketing 15

Marketing Venture Capitalist Biotechnology IPO 15

Harvard Business Review

MAY 1, 2014

I learned this while leading a turnaround of NPS Pharmaceuticals , a biotechnology company that now specializes in creating treatments for rare diseases. To save the 20-year-old company, I had to get it operating like a start-up. In the process, I came up with six rules that could also help others change their cultures.

Company 13

Company Pharmaceuticals Biotechnology Short-term 13

Harvard Business Review

JULY 11, 2018

To focus on businesses that are closer in spirit to the prototypical high-tech startup, we used a variety of indicators: whether the firm was granted a patent, received VC investment, or operated in an industry that employs a high fraction of STEM workers. In light of this evidence, why do some VCs persist in betting on young founders?

Succession 15

Succession IPO Entrepreneur Biotechnology 15

Harvard Business Review

MARCH 28, 2012

billion to acquire the webOS operating system, Hewlett-Packard discontinued its webOS-based series of smartphones and line of Touchpad tablets — losing its bet on a webOS-everywhere future. By answering these five questions: 1. Have we really seen the future or are we just rolling the dice? Just 13 months after buying Palm for $1.2

Innovation 14

Innovation Company Biotechnology CFO 14

Harvard Business Review

SEPTEMBER 21, 2018

This isn’t all that surprising given the level of innovation activity in these sectors, but directors operating in similarly disrupted sectors should take note. Just over one-fifth (22%) of boards operating in the IT and telecom industry sought tech expertise when filling their most recent board seat, higher than in any other industry.

Innovation 14

Innovation Short-term Telecommunications Long-term 14

Harvard Business Review

SEPTEMBER 14, 2011

Chirotech specializes in biocatalysis and chemocatalysis, two important subspecialties of biotechnology and chemistry that help develop key biological and chemical intermediates needed for the efficient production of medicines. You can't run your global R&D operations from headquarters in Mumbai. facility in Cambridge Science Park.

Globalization 11

Globalization Innovation Decentralization Chemicals 11

Harvard Business Review

MARCH 17, 2014

As the sector grows through this period of creative destruction, models that don’t work will die out, models that survive will attract copycats, operating costs will go down, and winners will rise to the top. We allowed microfinance and the venture capital industry the time and space to develop over a few decades.

Development 11

Development Microfinance Biotechnology Exit Strategy 11

Harvard Business Review

MARCH 5, 2012

This tight connection between R&D, innovation, and production is present in sectors like biotechnology, advanced materials, and nanotechnology. Ironically, American manufactures often cannot find workers with the technical and vocational skills required in today's sophisticated manufacturing operations. The Right Policies.

Health Care 10

Health Care Biotechnology Industry Policies 10

Harvard Business Review

JULY 16, 2013

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., The industry breakout was done using eight major sectors (similar to those in the Global Industry Classification Standard system): Consumer Discretionary (e.g., banking & financial services, insurance, real estate); Health Care (e.g.,

Telecommunications 10

Telecommunications Health Care Biotechnology Real Estate 10

Harvard Business Review

JUNE 23, 2015

Exciting applications have already been demonstrated across all sectors — from aerospace and medical applications to biotechnology and food production. In these cases, 3D printing has to compete with scale-driven manufacturing processes and rather efficient logistics operations. The Future of Operations. Insight Center.

Supply Chain 8

Supply Chain Tacit Knowledge Contract Manufacturing Biotechnology 8

Harvard Business Review

OCTOBER 23, 2014

That’s why pharmaceutical, biotechnology, and medical device companies need to define their relevance in this new health care ecosystem, and soon. They’re also sharing risk. The new business model has yet to solidify, and the leaders have yet to emerge. The positions are there for the taking. But not for long.

Health Care 9

Health Care Pharmaceuticals Information Technology Supply Chain 9

Harvard Business Review

JUNE 4, 2018

operational headquarters in Lexington, Massachusetts, which has been working with nearby Quincy College for the past several years. We were founded in 1885, to work with industry, and that is still a core mission for Georgia Tech.” ” Yet another example of a business/education partnership is Shire, a biotech company with U.S.

Education 8

Education Company Biotechnology Human Capital 8

Harvard Business Review

JUNE 16, 2016

“But here, we can operate within the time frame of the next coffee break.” Firms have also invested additional money to build facilities near the hubs to better integrate their operations with them. ” That’s really essential, because the different players often have widely divergent incentives. Dr. Mukesh V.

Technology 8

Technology Venture Capitalist Supply Chain Innovation 8

Harvard Business Review

JULY 22, 2015

.” Hanguk was a large, fast-growing company with diversified interests spanning electronics, biotechnology, shipping, construction, and chemicals. Its most successful division, mobile telephony, was looking for a new head of software development at headquarters in Seoul.

Case Study 8

Case Study Career Biotechnology Course 8

Harvard Business Review

FEBRUARY 3, 2015

Uzzi and another colleague, Jarrett Spiro, also discovered that this pattern held across sectors as disparate as the Broadway mu­sical industry and biotechnology. ✓ You need operational, personal, and strategic networks to get things done, to develop personally and professionally, and to step up to leadership.

How To 8

How To Diversity Letter Learning-by-Doing 8

Harvard Business Review

MARCH 30, 2017

We worked with a startup biotechnology company. an engineering culture, an operational culture, or a relational culture), we stifle the natural cognitive diversity in groups through the pressure to conform. It cannot be predicted or easily orchestrated. When we have a strong, homogenous culture (e.g.,

Diversity 8

Diversity Team Biotechnology Execution 8

Harvard Business Review

SEPTEMBER 11, 2014

For example, a wide variety of clean technologies (including wind, solar, and hydrogen) are vying to power vehicles and cities at the same time that a wide variety of medical technologies (chemical, biotechnological, genomic, and robotic) are being developed to treat diseases. Consider the 2×2 matrix below.

Uncertainty 22

Uncertainty Industry Bottom-up Technology 22

Harvard Business Review

MAY 15, 2015

Mary Shelley told us nothing about the future of biotechnology, but the popularity and plausibility of Frankenstein: The Modern Prometheus tells us a lot about 1818’s fears and aspirations for technology and its relation to society. Taken as a whole, science fiction’s predictions do not outperform random chance.

Class 8

Class Open-book Politics Biotechnology 8

Harvard Business Review

AUGUST 23, 2016

Boards of companies operating in the consumer discretionary industry have a disproportionately high representation of Democrats, while boards operating in the industrials and energy and utilities industries skew more Republican. pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g.,

Politics 8

Politics Committee Telecommunications Diversity 8